STRO

Sutro Biopharma

STRO, USA

Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

https://www.sutrobio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
STRO
stock
STRO

RBF Capital LLC Purchases New Position in Sutro Biopharma, Inc. $STRO MarketBeat

Read more →
STRO
stock
STRO

Velan Capital Investment Management LP Acquires 2,030,000 Shares of Sutro Biopharma, Inc. $STRO MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$2.6857

Analyst Picks

Strong Buy

4

Buy

0

Hold

5

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.96

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

65.15 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.12 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-396.57 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 63.44% of the total shares of Sutro Biopharma

1.

Suvretta Capital Management, LLC

(7.6537%)

since

2025/06/30

2.

Kynam Capital Management, LP

(6.0019%)

since

2025/06/30

3.

Millennium Management LLC

(5.5822%)

since

2025/06/30

4.

Vanguard Group Inc

(4.8544%)

since

2025/06/30

5.

Velan Capital Investment Management LP

(3.6096%)

since

2025/06/30

6.

Merck & Co Inc

(3.2127%)

since

2025/06/30

7.

Vestal Point Capital LP

(3.067%)

since

2025/06/30

8.

TANG CAPITAL MANAGEMENT LLC

(3.0217%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(2.7885%)

since

2025/07/31

10.

Eversept Partners, LLC

(2.704%)

since

2025/06/30

11.

Samsara BioCapital, LLC

(2.5914%)

since

2025/06/30

12.

BlackRock Inc

(2.4854%)

since

2025/06/30

13.

Adage Capital Partners Gp LLC

(2.3592%)

since

2025/06/30

14.

UBS Group AG

(1.9096%)

since

2025/06/30

15.

AQR Capital Management LLC

(1.1946%)

since

2025/06/30

16.

Renaissance Technologies Corp

(1.0772%)

since

2025/06/30

17.

Geode Capital Management, LLC

(0.9636%)

since

2025/06/30

18.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9618%)

since

2025/07/31

19.

Affinity Asset Advisors, LLC

(0.8879%)

since

2025/06/30

20.

Jane Street Group LLC

(0.8126%)

since

2025/06/30

21.

Dimensional Fund Advisors, Inc.

(0.7413%)

since

2025/06/30

22.

Goldman Sachs Small Cp Val Insghts Instl

(0.5516%)

since

2025/04/30

23.

iShares Biotechnology ETF

(0.5509%)

since

2025/08/31

24.

Dafna Capital Management LLC

(0.5156%)

since

2025/06/30

25.

Fidelity Extended Market Index

(0.4827%)

since

2025/07/31

26.

Vanguard US Value Factor ETF

(0.465%)

since

2025/06/30

27.

Fisher US Small Cap Opportunities

(0.4163%)

since

2025/06/30

28.

Goldman Sachs Small Cap Eq Insghts Instl

(0.2992%)

since

2025/04/30

29.

DFA US Small Cap I

(0.226%)

since

2025/07/31

30.

iShares Micro-Cap ETF

(0.208%)

since

2025/08/31

31.

Extended Equity Market Fund K

(0.19%)

since

2025/06/30

32.

Fidelity Total Market Index

(0.1596%)

since

2025/07/31

33.

Dimensional US Small Cap ETF

(0.151%)

since

2025/08/29

34.

Fidelity Series Total Market Index

(0.1275%)

since

2025/07/31

35.

Invesco RAFI US 1500 Small-Mid ETF

(0.1153%)

since

2025/08/29

36.

Spartan Extended Market Index Pool F

(0.1105%)

since

2025/07/31

37.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.1082%)

since

2025/03/31

38.

Northern Trust Extended Eq Market Idx

(0.1015%)

since

2025/06/30

39.

NT Ext Equity Mkt Idx Fd - L

(0.1015%)

since

2025/06/30

40.

abrdn Healthcare Investors

(0.0819%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.5573

EPS Estimate

-0.4183

EPS Difference

-0.139

Surprise Percent

-33.2297%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Wide Moat Company(6.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.